CEO James Brady Washburn Advocates for Compassionate Innovation in Wound Care
As the demand for high-quality, patient-centered wound care grows across the U.S., James Brady Washburn, CEO of Mid South Wound LLC, is calling on healthcare providers and leaders to reframe how they approach care for chronic wounds and post-acute recovery patients. His message: 'Wound care is not just clinical—it's personal. It's where compassion meets consistency.'
Washburn, a seasoned healthcare executive and former Division I football player, now leads one of the region's most respected wound care companies, known for its commitment to bedside excellence and provider-driven innovation. Under his leadership, Mid South Wound LLC has grown into a trusted resource for long-term care facilities, hospitals, and rehabilitation centers.
'We're treating more than wounds—we're treating people who are often overlooked in a fast-moving healthcare system,' Washburn said. 'They need advocates. They need dignity. That starts with showing up every day with purpose.'
A Call to Prioritise Underserved Patients
According to the National Institutes of Health, an estimated 6.7 million Americans live with chronic wounds, and that number is expected to rise due to aging populations and increasing rates of diabetes and obesity. Yet wound care remains an underfunded and underrecognised area in the broader healthcare landscape.
Washburn believes this gap must be addressed with urgency.
'We have some of the most vulnerable people—seniors, veterans, patients recovering from surgery—suffering in silence,' he explained. 'If wound care is done right, it restores not just skin, but confidence, mobility, and quality of life.'
Leadership Rooted in Discipline and Legacy
Washburn's personal background adds weight to his message. The son of longtime NFL coach Jim Washburn and brother of Jeremiah Washburn, current coach for the Philadelphia Eagles, Brady grew up immersed in the values of discipline, teamwork, and relentless preparation.
He played college football at Clemson University and Appalachian State University, before earning a Bachelor of Business Administration from Lipscomb University in 2007. These experiences shaped his leadership style—driven yet humble, strategic yet grounded in relationships.
'Football taught me to lead under pressure,' Washburn said. 'But it also taught me to respect every role on the team. That's how I lead our clinicians—like teammates, not staff.'
Bridging Innovation and Humanity
At Mid South Wound LLC, Washburn oversees strategic growth, provider recruitment, and clinical quality. But he stays connected to the day-to-day work of care teams and patients.
He advocates for healthcare companies to balance business efficiency with empathy—especially in fields like wound care, where treatment is often intimate and ongoing.
'You can't automate human touch,' he said. 'That's why I push for training, collaboration, and systems that support—not replace—the caregiver.'
Washburn is currently preparing to launch Mid South Wound's new website, which will serve as a resource for facilities, partners, and families seeking expert wound care services in the Southeast.
What the Public Can Do
Washburn encourages individuals and families to:
Ask more questions about wound care options for loved ones in nursing homes or hospitals
Support local clinicians and nurses who provide ongoing wound care treatment
Advocate for better funding and awareness in post-acute and chronic wound care
Explore careers in wound care, which offers high demand and meaningful patient impact
'If you know someone recovering from surgery, in long-term care, or with a chronic condition—ask how their wound care is being handled,' Washburn urged. 'Your attention might change their outcome.'
Final Word: Lead With Integrity, Serve With Heart
Whether it's mentoring his son, Cash Washburn, a rising football recruit, or managing a growing clinical operation, Washburn keeps one principle at the center of it all—service through leadership.
'Leadership isn't about being loud,' he said. 'It's about lifting others up and building something that lasts. In football, in business, and in healthcare—it all comes back to that.'
CALL TO ACTION
Don't overlook wound care—it's where healing begins. Learn how you can support patients, caregivers, and wound care professionals in your own community. Awareness, action, and compassion go a long way.
Media Contact: Read the full Interview, here.
Email: jameswashburn@emaildn.com
Media Contact
Contact Person: James Brady Washburn
Email: Send Email
Country: United States
Website: https://www.crunchbase.com/person/james-brady-washburn
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Minister of Social Development gets more power after changes to Nursing Home Act in New Brunswick
The Department of Social Development now has the ability to fast-track patients from hospital beds to nursing homes in New Brunswick after the province made changes to the Nursing Home Act. According to a news release from the province on Friday, changes will eliminate the previous 'critical state' admission process for alternate-level-of-care patients waiting for nursing home placements and allow the Minister of Social Development to interrupt if over the previous seven days, hospital bed occupancy has exceeded 95 per cent and more than 25 per cent of those beds were alternate-level-of-care patients. 'We know this situation didn't develop overnight, and, while it won't be solved overnight, our government is tackling it head-on with a commitment to lasting change for New Brunswickers,' said Social Development Minister Cindy Miles in the release. 'We're focused not only on short-term solutions, but also on building the right supports and services in our communities to create a more sustainable future.' The new wait-list management process can take effect for up to 120 days in the province's eight regional hospitals. After that time the province says the minister may consider whether it should be extended. 'By prioritizing these patients for nursing home placement when hospital occupancy is critically high, we can improve patient flow, reduce overcrowding, and ensure patients are cared for in the most appropriate setting for their needs,' said Margaret Melanson, president and CEO of the Horizon Health Network in the release. Additionally, the province says the department may prioritize for nursing home admission people in the community who are deemed to be at exceptional risk with respect to health and safety. People approved under this process will supersede admissions from hospitals. 'This reform will help us keep our hospital beds available for patients who need them most, while providing those waiting for long-term care with an environment better suited to their needs,' said Jenny Toussaint, vice-president of clinical logistics at Vitalité Health Network in the release. A total of 640 nursing home beds have been awarded since 2021 under the 2018–2023 Nursing Home Plan; 460 of those beds have opened, with another 180 currently under construction. Social Development is currently developing a new long-term care plan, including a five-year nursing home plan that expected to be released later this fall. For more New Brunswick news, visit our dedicated provincial page.
Globe and Mail
7 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
CTV News
9 hours ago
- CTV News
Alberta COVID-19 vaccination program triggers confusion, criticism
Medical tools are pictured in an exam room at a health clinic in Calgary, Friday, July 14, 2023. THE CANADIAN PRESS/Jeff McIntosh Health experts, advocates and unions are sounding the alarm over Alberta's plan for paid COVID-19 shots, calling it concerning and confusing. On Monday, two months after the province announced it was adding a fee, it opened online pre-ordering for the vaccine. Albertans still need to book appointments for the shots, starting in October. Dr. James Talbot, the province's former chief medical officer of health, said the government appears to be doing everything it can to make this year's immunization campaign a 'failure' by making it less available, less accessible and less affordable. 'They are basically sabotaging their own COVID campaign,' he said. Dr. James Talbot Dr. James Talbot, co-chair of the EZMSA strategic COVID-19 pandemic committee, said in an interview with CTV News Edmonton that EZMSA has been predicting for four weeks now that variants would drive a significant third wave of COVID-19 cases (CTV News Edmonton). He's among a chorus of critics warning it could lead to more hospitalizations and stress on the health-care system. Talbot and other public health experts and physicians penned an opinion piece in the Edmonton Journal last week, arguing the plan creates unfair barriers and puts Albertans at risk. 'You've created this unfairness where if you're rich, you can get protected, but if you're poor, you may not be able to,' Talbot said. Extreme outlier Leigh Allard, president and CEO of Alberta Lung, part of the National Lung Health Alliance, said the government's policy makes it an extreme outlier and its precedent could ripple across the country. Those who suffer from lung conditions like asthma, cystic fibrosis or pulmonary fibrosis are vulnerable, she added. This year, Albertans also won't be able to walk into a pharmacy to get a COVID-19 shot, where the vast majority of doses were given last year. They must go to a public health clinic. Allard said people are confused over the plan. She's also concerned many won't be able to access a clinic for a shot, especially if hours aren't extended, or some simply won't be able to afford it. She said she expects an uptake in Alberta Lung's financial assistance programs. 'As a charity, we should not be supplementing what the government should be doing.' The government said it will still pay for some to get shots, including those who have compromised immune systems or are on social programs. Seniors in congregate settings will also be covered. However, the specifics of the qualifying health conditions have not been released. It's estimated a shot could cost $110, but the government has yet to pin down the price. Kyle Warner, spokesperson for Primary and Preventative Health Minister Adriana LaGrange, said details are forthcoming. 'The fall immunization plan is being finalized, and details — including the updated vaccination schedule, eligible conditions, exact locations and administrative fee for COVID-19 vaccines — will be available soon,' he said in a statement. Warner also said Albertans who don't pre-order by the Sept. 30 deadline can still book a vaccine appointment once doses become available. He said online pre-ordering helps determine future vaccine needs, minimize waste, manage delivery and prevent double bookings, since the influenza vaccine can be given at the same time. Those who pre-order are promised a reminder in October to book an appointment. The province said it has ordered 485,000 doses of COVID-19 vaccine for the fall and some of the estimated $49-million cost would be covered through those who have to pay. The government didn't respond to questions about whether it has a contingency plan to order more doses if needed, whether out-of-province costs might be reimbursed, and what informed its decision to order 250,000 fewer doses than last year. It also didn't clarify whether flu shots, which remain free, would be available in pharmacies. The province's interim chief medical officer of health, Dr. Sunil Sookram, wasn't made available for an interview. Disrespectful Talbot called withholding the specifics disrespectful. 'It's bad enough that there's a list that says you're going to ration it, but then to have confusion about who's on the list — that just seems cruel,' he said. The province has said an estimated one million COVID-19 vaccine doses, or just over half of Alberta's supply, weren't used during the 2023-24 respiratory virus season. Premier Danielle Smith has said that meant $135 million was 'flushed down the drain.' Facing heated questions about the policy at a public town hall in Edmonton on Thursday, Smith said her United Conservative Party government is trying not to waste public money. 'There are lots of different types of vaccines that are paid for out of pocket right now ... because the federal government defunded it,' she said, pointing to shots for yellow fever, which also need to be purchased. The latest provincial data says 394 Albertans with confirmed COVID-19 have died since last August. Talbot and labour leaders have also said the plan puts health workers in harm's way, and potentially forces those in an already strained system to take sick time off work to avoid infecting others. 'You're going to be the only province in the country that says we care so little about these people that we're going to force them to pay for their own vaccine,' said Talbot. 'It seems inconceivable to me that a rational mind would think that was a good way to recruit and retain health-care professionals.' Potential fallout Unions warned this week of potential fallout. In a Tuesday letter to the premier, Alberta Federation of Labour president Gil McGowan wrote it would be a violation of workplace health and safety laws not to include all health workers, education workers, transit operators and those in the service sector on its priority list. McGowan said he's also hearing frustration and confusion from front-line members. 'It's not just incompetence. This is clearly not a vaccine rollout strategy. It's a vaccine suppression strategy,' he said. The United Nurses of Alberta has said the plan limits the freedom of Albertans to choose vaccination by intentionally limiting supply and penalizing those who can't afford it. --Lisa Johnson This report by The Canadian Press was first published Aug. 16, 2025.
